Skip to main content

Peer Review reports

From: First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study

Original Submission
27 Aug 2023 Submitted Original manuscript
31 Aug 2023 Author responded Author comments - Dominik Soll
5 Nov 2023 Reviewed Reviewer Report
21 Nov 2023 Reviewed Reviewer Report
7 Dec 2023 Author responded Author comments - Dominik Soll
Resubmission - Version 2
31 Aug 2023 Submitted Manuscript version 2
10 Dec 2023 Author responded Author comments - Dominik Soll
Resubmission - Version 3
10 Dec 2023 Submitted Manuscript version 3
15 Dec 2023 Reviewed Reviewer Report
22 Dec 2023 Reviewed Reviewer Report
3 Jan 2024 Reviewed Reviewer Report
28 Jan 2024 Author responded Author comments - Dominik Soll
Resubmission - Version 4
28 Jan 2024 Submitted Manuscript version 4
29 Jan 2024 Author responded Author comments - Dominik Soll
Resubmission - Version 5
29 Jan 2024 Submitted Manuscript version 5
30 Jan 2024 Reviewed Reviewer Report
8 Feb 2024 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
9 Feb 2024 Editorially accepted
22 Feb 2024 Article published 10.1186/s12902-024-01555-y

You can find further information about peer review here.

Back to article page